Commercial Services and Supplies
Company Overview of Cancer Research UK
Cancer Research UK is a charitable institution that supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The charity also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. The institute also operates an online portal CancerHelp UK that provides patient information. Cancer Research UK was incorporated in 2001 and is based in London, United Kingdom.
407 St. John Street
London, EC1V 4AD
Founded in 2001
Key Executives for Cancer Research UK
Chief Executive Officer and Chairman of the Executive Board
Compensation as of Fiscal Year 2014.
Cancer Research UK Key Developments
MedImmune Enter into Collaboration with Cancer Research UK and Cancer Research Technology to Jointly Establish Biologic Cancer Medicine Lab
Sep 29 14
MedImmune has entered into a collaboration with Cancer Research UK and its Cancer Research Technology (CRT). The collaboration is intended to jointly establish a laboratory in Cambridge, UK, to focus on the discovery and development of novel biologic cancer treatments over an initial five-year period. Scientists from both organizations will work side-by-side on multiple oncology projects at the new CRUK-MEDI Alliance Laboratory. Cancer Research UK, will provide set-up and operational funding for the laboratory and will contribute a portfolio of novel drug targets together with a team of scientists. MedImmune will oversee the laboratoryactivities and provide access to its human antibody phage display libraries and established antibody-engineering technologies. The joint team will share knowledge and expertise to discover and develop antibodies to treat cancer.
Cancer Research UK, Cancer Research Technology and Asterias Biotherapeutics Inc. Partner to Trial Immunotherapy Vaccine for Lung Cancer
Sep 11 14
CANCER RESEARCH UK and Cancer Research Technology (CRT) have reached an agreement with Asterias Biotherapeutics, Inc. to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. AST-VAC2 represents the tenth treatment to enter Cancer Research UK's Clinical Development Partnerships (CDP) scheme, with six having progressed into the clinic to date. CDP is a joint initiative between Cancer Research UK's Drug Development Office (DDO) and Cancer Research Technology, to develop promising anti-cancer agents which pharmaceutical companies do not have the resources to progress through early phase clinical trials. AST-VAC2 is a non-patient specific (allogeneic) cancer vaccine designed to stimulate patients' immune systems to attack telomerase, a protein that is expressed in over 95% of cancers but is rarely expressed in normal adult cells. The vaccine was developed following successful early phase clinical trials of a similar, patient specific (autologous) Asterias vaccine, called AST-VAC1, which was derived from patients' blood cells and tested in prostate cancer and acute myeloid leukemia. Unlike AST-VAC1, and other autologous (patient specific) vaccines that are developed from a patient's own cells, AST-VAC2 is derived from human embryonic stem cells (hESCs), meaning it can be produced on a large scale and stored ready for use, rather than having to produce a specific version of the drug for each patient. The trial of AST-VAC2 will evaluate the safety and toxicity of the vaccine, feasibility, stimulation of patient immune responses to telomerase and AST-VAC2, and clinical outcome after AST-VAC2 administration in patients with resected early-stage lung cancer and in patients with advanced forms of the disease. Under the agreement, Asterias will complete development of the manufacturing process for AST-VAC2. Cancer Research UK will then produce the vaccine and conduct the phase 1/2 clinical trial in the UK. On completion of the clinical trial, Asterias will have an exclusive first option to acquire a license to the data from the trial on pre-agreed terms including an upfront payment, milestones and royalties on sales of products. If Asterias declines this option, CRT will then have an option to obtain a license to Asterias' intellectual property to continue the development and commercialisation of AST-VAC2 and related products in exchange for a revenue share to Asterias of development and partnering proceeds.
Cancer Research UK and Cancer Research Technology Join Forces with Astellas Pharma, Inc. on Autophagy to Find New Cancer Treatments
Aug 8 14
Cancer Research UK and Cancer Research Technology are to join forces with Astellas Pharma Inc. to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer. As part of a new collaboration, Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer. Certain pancreatic cancers are dependent on autophagy, the process of consuming own cellular parts for energy, in order to grow. Blocking this pathway may help stop some pancreatic cancers. Under the terms of the deal, the first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells. This research will be carried out by Professor Kevin Ryan at the Cancer Research UK Beatson Institute and Dr. Sharon Tooze at the Cancer Research UK London Research Institute. Astellas has an exclusive licence to progress the most promising candidates through further drug discovery and development, subject to certain milestone and royalty payments to CRT. New treatments are desperately needed for pancreatic cancer -- one of the deadliest forms of cancer. Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only 3% of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|